Introduction: This variant (Epsilon) comprises two separate lineages B.1.427 and B.1.429, the first carrying two spike mutations (L452R, D614G) and the second carrying four (S13I, W152C, L452R, D614G).
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
Discussion: An alternative (but not mutually exclusive) possibility is that the additional mutations in B.1.427/B.1.429, especially the W152C and S13I mutations in the spike protein, may contribute to in
Discussion: In the current study, we describe the spread of a novel B.1.427/B.1.429 variant in California carrying a characteristic triad of spike protein mutations (S13I, W152C, and L452R) that is predicted to have emerged in May 2020 and increased in frequency from 0% to >50% of sequenced cases from September 2020 to January 2021.
Discussion: Indeed, in the current study we observed smaller but statistically significant increases in infection of 293T cell and lung organoids by pseudoviruses carrying W152C.
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.
Abstract: It is unclear whether antibody responses to SARS-CoV-2 infection or to the prototypic Wuhan-1 isolate-based vaccines will be impacted by the three B.1.427/B.1.429 S mutations: S13I, W152C and L452R.
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K.
Introduction: 11 Virtually all variants of concern contain mutations in the SARS-CoV-2 Spike protein, such as variant B.1.351 (Spike mutations K417N, E484K, N501Y, D614G, and A701V) and variants B.1.427/B.1.429 (Spike mutations S13I, W152C, L452R, and D614G), and many of these reside on the receptor-binding domain (RBD), a region located between residues 350-550 of Spike and directly binding to the human ACE2.
The Spike of Concern-The Novel Variants of SARS-CoV-2.
8Discussion: The new emergent lineage B.1.429, which has a substitution in the same codon 152 (W152C), was first identified in California, United States; this lineage is defined as a ""Variant of Interest"" by the US Centers for Disease Control and Prevention (CDC)."
Discussion: The W152C mutation is located in the NTD antigenic supersite (designated site i) and is also associated with reduced recognition of the NTD by neutralizing monoclonal antibodies.
2020 SARS-CoV-2 diversification in the United States: Establishing a pre-vaccination baseline.
Introduction: Mutations defining the B.1.427/429 VOC (SS13I;W152C;L452R) which originated in the U.S., were only detected in a very small fraction of sequences in Dec 2020, possibily due to the lag between sample collection and sequence deposition and/or shallow Phase 3 sampling.
Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning Strategy.
Result: The S13I and W152C mutations, which are situated in the N-terminal domain (NTD) of the Spike protein, have been implicated in escape from NTD-targeting monoclonal antibodies.
Result: The VRV-haplotype S13I-W152C-L452R (ICR-3) appeared in Fall 2020 and is rapidly becoming dominant in states on the West Coast, as well as appearing in selected Southwestern and Southeastern states.
SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity.
Method: Plasmids expressing the SARS-CoV-2 S protein mutants (pC-S-L452R, pC-SARS2-S-Y453F
Figure: The HIV-1-based reporter virus pseudotyped with the parental SARS-CoV-2 S or its derivatives (E, L452R, Y453F, and N501Y; F, D614G, B.1.429 [S13I/W152C/L452R/D614G], and B.1.1.298 [HV69-70del/Y453F/D614G]) was inoculated into HEK293 cells transiently expressing human ACE2 and TMPRSS2 at four different doses (1, 3, 5, and 10 ng p24 antigens).
SARS_CoV_2 mutation literature information.
PMID: 
2021
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT